Gainers
- Tivic Health Systems TIVC stock moved upwards by 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million.
- Doximity DOCS shares moved upwards by 39.82% to $60.71. The company's market cap stands at $11.2 billion. As per the press release, Q2 earnings came out yesterday.
- Xilio Therapeutics XLO shares increased by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday.
- Eyenovia EYEN shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million.
- Fortrea Holdings FTRE shares increased by 13.68% to $20.52. The company's market cap stands at $1.8 billion. The company's, Q3 earnings came out today.
- CytomX Therapeutics CTMX shares increased by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the press release, Q3 earnings came out yesterday.
Losers
- ProPhase Labs PRPH shares fell 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million.
- Evolent Health EVH stock fell 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday.
- Agilon Health AGL stock declined by 31.9% to $1.9. The market value of their outstanding shares is at $781.8 million. As per the news, the Q3 earnings report came out yesterday.
- Maravai LifeSciences MRVI shares fell 28.19% to $5.63. The company's market cap stands at $796.9 million. As per the news, the Q3 earnings report came out yesterday.
- Revance Therapeutics RVNC stock declined by 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday.
- AlloVir ALVR shares decreased by 14.42% to $0.84. The market value of their outstanding shares is at $96.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in